Paul F. Schellhammer
YOU?
Author Swipe
View article: Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Open
To develop an evidence-based guideline on the use of 5-α-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention.
View article: Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry Open
Purpose African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving si…
View article: Oestrogen redux: will transdermal delivery rebalance the risk–benefit equation?
Oestrogen redux: will transdermal delivery rebalance the risk–benefit equation? Open
Between 1960 and 1975, the Veterans Association Cooperative Urological Research Group (VACURG) conducted a series of large randomized trials to test several oestrogenic compounds in varying doses and combinations with regard to their effic…
View article: A Urologist’s Personal View of Prostate Cancer
A Urologist’s Personal View of Prostate Cancer Open
A urologist's personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advanced prostate cancer and thoughts on the role of old and new therapies.